Business Services Industry
Mylan Speaks To Zagam
Business Wire, Feb 16, 2001
Business Editors
PITTSBURGH--(BUSINESS WIRE)--Feb. 16, 2001
Mylan Laboratories Inc. (NYSE:MYL) has indicated that they are presently marketing the antibiotic, Zagam(R), and it remains a part of their Bertek branded product line.
Mylan wrote down $3.6 million of the Zagam(R) product license asset in their third quarter, which was reported on January 30, 2001, because of supply issues.
Mylan continues to work to try and resolve the issues surrounding Zagam(R).
Mylan Laboratories Inc., is one of the largest manufacturers and marketers of prescription generic pharmaceuticals in the United States. Mylan also develops and markets branded pharmaceutical products through its Bertek Pharmaceuticals Inc. subsidiary.
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Getting the global view: Nestle, led by Peter Brabeck-Letmathe, climbs to the #1 spot in this year's Best Companies for Leaders
Most Popular Business Publications
Content provided in partnership with
